References
- Polansky H. Cancer, Microcompetition with foreign DNA and the origin of chronic disease. Rochester, New York: CBCD Publishing; 2003. p 303–32.
- Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, . Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160–4.
- Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia associated with adjuvant anthracycline/taxane regimens. Clin Breast Cancer 2008;8:352–6.
- Nilsson A, De Milito A, Engström P, Nordin M, Narita M, Grillner L, . Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109:633–6.
- Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, . Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res 2003;9:174–80.
- Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A . Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study. Br J Cancer 2009;100:1842–5.Epub 2009 Jun 2.
- Sakamoto J, Kondo Y, Takemiya S, Sakamoto N, Nishisho I; Clinical Study Group of Capecitabine. A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. Anticancer Drugs 2004;15:137–43.
- Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, . Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009;27:1753–60.
- Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, . All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: An International Phase II Trial. Br J Cancer 2009;101:232–7. Epub 2009 Jul 7.
- Bogenrieder T, Weitzel C, Schölmerich J, Landthaler M, Stolz W. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: A lesson for the pathogenesis of malignant melanoma? Dermatology 2002;205:174–5.
- Nishida M. Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine. Nippon Yakurigaku Zasshi 2003;122:549–53.
- Dong N, Jiang W, Li H, Liu Z, Xu X, Wang M. Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am J Clin Oncol 2009 Jul 2. [Epub ahead of print]
- Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63:217–36.